Diagnosis, Dual (Psychiatry)
Conditions
Keywords
Psychiatric Dual Diagnosis, Integrated Attention, Program
Brief summary
Aim: validate a Dual Integrated Attention Program (D-AIP) for mental health nursing in people with Severe Dual Diagnosis admitted to a psychiatric hospitalization unit Design: Randomized Controlled Trial. Population: Inpatients with dual diagnosis.
Detailed description
The main objective of the project is to validate a Dual Integrated Attention Program (D-AIP) for mental health nursing in people with Severe Dual Diagnosis admitted to a psychiatric hospitalization unit, assessing change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety, which this context generates. For this purpose, a randomized, prospective, one-year-longitudinal clinical trial will be conducted. This study will be applied on patients with diagnosis of schizophrenia, schizoaffective disorder and bipolar disorder types I and II who, after accepting to participate in the study and signing the informed consent, answer the PRISM questionnaire of admission in the hospitalization unit and fulfill the dual pathology criteria. After, they will be randomized in control group and intervention group (only the later will complete the D-AIP). The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and during follow-up up to one year after discharge in which 4 individual sessions and 3 telephone contacts will be made. In both groups, a different person from the one who performs the intervention and without knowledge of the group belonging will assess them with questionnaires in 9 moments during the whole follow-up year (Socrates 8D, Scale of Unawareness of Mental Disorder SUMD, Morisky Medication Adherence Scale MMAS-8, Working Alliance Inventory WAI, Hamilton Anxiety Rating Scale HARS y Hopelessness Scale HS) and will collect a urine sample in each evaluation. The sample size will be 86 subjects, for α=0.05 and power=0.80.
Interventions
BEHAVIORALD-AIP
Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
Sponsors
Cardenal Herrera University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
Randomized Controlled Trial (Parallel Assignment)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Inpatients diagnosed with some serious mental illness of the following: * Inpatients with diagnosis of schizophrenia * Inpatients with diagnosis schizoaffective disorder * Inpatients with diagnosis bipolar disorder types I * Inpatients with diagnosis bipolar disorder types II 2. Consumption of addictive substances
Exclusion criteria
* Intellectually Disabled
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hopelessness | 12 months | Assessed by Hopelessness Scale (HS) |
| Insight | 12 months | Assessed by Scale Unawareness of Mental Disorders (SUMD) |
| Medication Adherence | 12 months | Assessed by Medication Adherence Scale (MMAS-8) |
| Therapeutic Alliance | 2-3 months | Assessed by Working Alliance Inventory in patients and therapist (WAI-P and WAI-T) |
| Anxiety | 12 months | Assessed by Hamilton Anxiety Rating Scale (HARS) |
| Stages of Change Readiness | 12 months | Assessed by Questionnaire SOCRATES 8D |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Drug use change | 12 months | Presence of drug abuse through a urine sample with 10-panel drug test |
| Hospital readmissions | 12 months | Number of registered hospital readmissions |
| Dual diagnosis knowledge | 12 months | Assessed by ad-hoc questionnaire |
| Containments methods | 2-3 months | Number of registered containments methods |
Contacts
Primary ContactMontse Cañabate, Dra.
Outcome results
None listed